BIOTECH TARGET N V

About BIOTECH TARGET N V

BIOTECH TARGET N V is an investment holding vehicle associated with BB Biotech AG, a Swiss biotechnology investment company whose portfolio exposure is held indirectly through wholly owned subsidiaries, including Biotech Target N.V., based in Curaçao. In U.S. regulatory filings, BIOTECH TARGET N V appears primarily as a significant shareholder and investment vehicle in publicly listed biopharmaceutical companies, including Molecular Templates, Inc., MacroGenics, Esperion Therapeutics, and Radius Health. Its public profile is therefore closer to that of an institutional investor than a conventional operating executive. From a governance perspective, the entity shows up in SEC filings as a holder of securities and a meaningful owner, which points to active oversight of portfolio positions, capital transactions, and strategic developments in the companies it backs. Public records indicate ownership and transaction activity involving Molecular Templates, Inc., along with reporting relationships tied to BB Biotech AG. This structure suggests a long-term value creation approach in life sciences, with emphasis on backing innovative companies, managing portfolio risk, and monitoring clinical, regulatory, and financial catalysts. Because BIOTECH TARGET N V is a holding/investment vehicle rather than a natural person executive, personal career history, traditional operating roles, and decisions attributable to one individual are not clearly established in the public sources reviewed. The most accurate framing is therefore as an influential institutional participant in listed biotechnology, with a U.S. market presence through significant holdings and shareholder governance activity.